Targeting Unmet Clinical Needs in Medically Vulnerable Patient Populations: SER-155 Phase 1b Trial Results in Allo-HSCT Patients
Time: 11:00 am
day: Conference Day One
Details:
- Leveraging a Phase 1b clinical trial strategy to evaluate safety and drug pharmacology, as well as obtain insights on clinical efficacy
- SER-155 safety was well-tolerated in both open-label patient cohort and placebo-controlled cohort
- Observation of significant reduction in both bacterial bloodstream infections (BSIs) and systemic antibiotic exposure with expected drug pharmacokinetics, as well as lower incidence of febrile neutropenia
